MedTrace Logo

M-CPP and Fenfluramine in Cocaine Addicts - 3

NCT00000314 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-01-18

No results posted yet for this study

Summary

The purpose of this study is to evaluate predictive value of M-CPP and fenfluramine challenges for outcome.

Conditions

  • Cocaine-Related Disorders

Interventions

DRUG

M-CPP

Sponsors & Collaborators

  • VA Office of Research and Development

    collaborator FED

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • Laure Buydens-Branchey, M.D. · VA Medical Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
25 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-09-30
Primary Completion
1999-08-31
Completion
1999-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000314 on ClinicalTrials.gov